13-methyltetradecanoic acid exhibits anti-tumor activity on T-cell lymphomas in vitro and in vivo by down-regulating p-AKT and activating caspase-3

PLoS One. 2013 Jun 7;8(6):e65308. doi: 10.1371/journal.pone.0065308. Print 2013.

Abstract

13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid purified from soy fermentation products, induces apoptosis in human cancer cells. We investigated the inhibitory effects and mechanism of action of 13-MTD on T-cell non-Hodgkin's lymphoma (T-NHL) cell lines both in vitro and in vivo. Growth inhibition in response to 13-MTD was evaluated by the cell counting kit-8 (CCK-8) assay in three T-NHL cell lines (Jurkat, Hut78, EL4 cells). Flow cytometry analyses were used to monitor the cell cycle and apoptosis. Proteins involved in 13-MTD-induced apoptosis were examined in Jurkat cells by western blotting. We found that 13-MTD inhibited proliferation and induced the apoptosis of T-NHL cell lines. 13-MTD treatment also induced a concentration-dependent arrest of Jurkat cells in the G1-phase. During 13-MTD-induced apoptosis in Jurkat cells, the cleavage of caspase-3 and poly ADP-ribose polymerase (PARP, a caspase enzymolysis product) were detected after incubation for 2 h, and increased after extending the incubation time. However, there was no change in the expression of Bcl-2 or c-myc proteins. The appearance of apoptotic Jurkat cells was accompanied by the inhibition of AKT and nuclear factor-kappa B (NF-κB) phosphorylation. In addition, 13-MTD could also effectively inhibit the growth of T-NHL tumors in vivo in a xenograft model. The tumor inhibition rate in the experimental group was 40%. These data indicate that 13-MTD inhibits proliferation and induces apoptosis through the down-regulation of AKT phosphorylation followed by caspase activation, which may provide a new approach for treating T-cell lymphomas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Blotting, Western
  • Caspase 3 / metabolism*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Down-Regulation / drug effects*
  • Enzyme Activation / drug effects
  • G1 Phase Cell Cycle Checkpoints / drug effects
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / enzymology*
  • Lymphoma, T-Cell / pathology
  • Mice
  • Mice, Nude
  • Myristic Acids / administration & dosage
  • Myristic Acids / pharmacology*
  • Myristic Acids / therapeutic use*
  • NF-kappa B / metabolism
  • Neoplasm Proteins / metabolism
  • Phosphorylation / drug effects
  • Poly(ADP-ribose) Polymerases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Xenograft Model Antitumor Assays

Substances

  • Myristic Acids
  • NF-kappa B
  • Neoplasm Proteins
  • Poly(ADP-ribose) Polymerases
  • Proto-Oncogene Proteins c-akt
  • Caspase 3
  • 13-methyltetradecanoic acid

Grants and funding

This work was supported by National Nature Scientific Research Fund of China (grant number: 81001052); Science and Technology Planning Project of Guangdong Province, China (grant number: 2011B031800222); Young Talents project of Sun Yat-sen University Cancer Center; Yat-sen Scholarship for Young Scientists (to Tianxin, Lin) and Program for New Century Excellent Talents in University (NCET-10-0852), to Tianxin, Lin and Guangdong Province Natural Scientific Grant (8151008901000043). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.